CN116510015A - 用于治疗自身免疫疾病和癌症的组合物及方法 - Google Patents

用于治疗自身免疫疾病和癌症的组合物及方法 Download PDF

Info

Publication number
CN116510015A
CN116510015A CN202310352979.8A CN202310352979A CN116510015A CN 116510015 A CN116510015 A CN 116510015A CN 202310352979 A CN202310352979 A CN 202310352979A CN 116510015 A CN116510015 A CN 116510015A
Authority
CN
China
Prior art keywords
siglec
modulator
lrrc4c
mag
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310352979.8A
Other languages
English (en)
Chinese (zh)
Inventor
陈列平
王俊
孙静玮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CN116510015A publication Critical patent/CN116510015A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
CN202310352979.8A 2015-11-10 2016-11-09 用于治疗自身免疫疾病和癌症的组合物及方法 Pending CN116510015A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562253437P 2015-11-10 2015-11-10
US62/253,437 2015-11-10
CN201680065576.3A CN108430498A (zh) 2015-11-10 2016-11-09 用于治疗自身免疫疾病和癌症的组合物及方法
PCT/US2016/061086 WO2017083354A1 (en) 2015-11-10 2016-11-09 Compositions and methods for treating autoimmune diseases and cancers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680065576.3A Division CN108430498A (zh) 2015-11-10 2016-11-09 用于治疗自身免疫疾病和癌症的组合物及方法

Publications (1)

Publication Number Publication Date
CN116510015A true CN116510015A (zh) 2023-08-01

Family

ID=58695157

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310352979.8A Pending CN116510015A (zh) 2015-11-10 2016-11-09 用于治疗自身免疫疾病和癌症的组合物及方法
CN201680065576.3A Pending CN108430498A (zh) 2015-11-10 2016-11-09 用于治疗自身免疫疾病和癌症的组合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680065576.3A Pending CN108430498A (zh) 2015-11-10 2016-11-09 用于治疗自身免疫疾病和癌症的组合物及方法

Country Status (13)

Country Link
US (2) US20180318419A1 (https=)
EP (2) EP3373962A4 (https=)
JP (4) JP6924495B2 (https=)
KR (1) KR102810368B1 (https=)
CN (2) CN116510015A (https=)
AU (2) AU2016354100B2 (https=)
BR (1) BR112018009361A8 (https=)
CA (1) CA3002095A1 (https=)
HK (1) HK1259294A1 (https=)
MX (2) MX2018005830A (https=)
RU (1) RU2761980C2 (https=)
TW (2) TWI847955B (https=)
WO (1) WO2017083354A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
DK3515478T3 (da) 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
CN113138273B (zh) * 2020-01-17 2024-06-18 孟民杰 一种应用于肺癌快速筛查及免疫靶向治疗检测的试剂盒及其用途
PH12022552520A1 (en) * 2020-03-27 2023-01-04 Biosion Inc Antibodies binding siglec15 and uses thereof
CN113817057B (zh) * 2020-06-19 2024-02-20 盛禾(中国)生物制药有限公司 一种抗siglec15抗体及其应用
CN114525256A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用
KR20230118131A (ko) * 2020-12-08 2023-08-10 구이조우 시노르다 바이오테크놀로지 씨오. 엘티디. 입양 면역요법을 위한 변형된 t 세포들
CN114657132A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达Siglec-15靶向抑制因子的多能干细胞及其衍生物与应用
ES2955819T3 (es) * 2021-01-21 2023-12-07 Guizhou Sinorda Biotechnology Co Ltd Linfocitos T modificados para inmunoterapia adoptiva
WO2022179483A1 (zh) * 2021-02-23 2022-09-01 上海济煜医药科技有限公司 Siglec-15结合蛋白的制备及其用途
CN114957468A (zh) * 2021-02-25 2022-08-30 石药集团巨石生物制药有限公司 一种抗Siglec15抗体及其用途
CN114751973B (zh) * 2021-03-12 2024-02-20 百奥赛图(北京)医药科技股份有限公司 Siglec15基因人源化非人动物的构建方法和应用
CN116983412A (zh) * 2023-08-04 2023-11-03 南通大学 Siglec-15-SE超增强子在制备治疗肿瘤的产品中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5807683A (en) 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
WO1997001352A1 (en) * 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
CN101670119A (zh) * 2001-11-21 2010-03-17 利兰·斯坦福青年大学托管委员会 多核苷酸
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
ES2453496T3 (es) * 2006-08-28 2014-04-08 Omnio Healer Ab Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral
BRPI0818437B8 (pt) * 2007-10-11 2021-05-25 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
MX343049B (es) 2009-04-09 2016-10-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
EP2542256B1 (en) * 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR20130108295A (ko) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
MX2013003828A (es) * 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
US20150299255A1 (en) * 2010-11-01 2015-10-22 Susavion Biosciences, Inc. Compositions and methods for modulating innate and adaptive immune systems
CA2848074A1 (en) * 2011-09-09 2013-03-14 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
EP2610263A1 (de) * 2011-12-30 2013-07-03 Brossmer, Reinhard Sialinsäure-Dimere
US20160264684A1 (en) * 2013-10-10 2016-09-15 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2015143091A1 (en) * 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties

Also Published As

Publication number Publication date
WO2017083354A1 (en) 2017-05-18
KR20180073691A (ko) 2018-07-02
MX2023012451A (es) 2023-10-31
JP2025156500A (ja) 2025-10-14
KR102810368B1 (ko) 2025-05-19
MX2018005830A (es) 2018-11-12
JP2023096078A (ja) 2023-07-06
CA3002095A1 (en) 2017-05-18
US20180318419A1 (en) 2018-11-08
AU2016354100B2 (en) 2023-11-30
TWI847955B (zh) 2024-07-11
TW201729841A (zh) 2017-09-01
AU2024201282A1 (en) 2024-03-14
EP4512827A2 (en) 2025-02-26
AU2016354100A1 (en) 2018-06-21
RU2018121050A (ru) 2019-12-13
EP3373962A1 (en) 2018-09-19
TW202330019A (zh) 2023-08-01
RU2018121050A3 (https=) 2020-03-13
JP6924495B2 (ja) 2021-08-25
RU2761980C2 (ru) 2021-12-14
JP2021167353A (ja) 2021-10-21
BR112018009361A8 (pt) 2019-02-26
US20220168419A1 (en) 2022-06-02
BR112018009361A2 (en) 2018-11-13
HK1259294A1 (zh) 2019-11-29
EP4512827A3 (en) 2025-04-30
EP3373962A4 (en) 2020-02-19
JP2018533591A (ja) 2018-11-15
CN108430498A (zh) 2018-08-21

Similar Documents

Publication Publication Date Title
US20220168419A1 (en) Compositions and methods for treating autoimmune diseases and cancers
JP6466401B2 (ja) ヒト化抗ｃｄ１９キメラ抗原受容体を使用するがんの処置
BR112020026386A2 (pt) Composições e métodos para modulação de fenótipos inflamatórios com monócitos e macrófagos e usos de imunoterapia dos mesmos
CN107074951B (zh) 拮抗性抗-ox40l抗体及其使用方法
AU2017268399A1 (en) Mrna combination therapy for the treatment of cancer
JP6366195B2 (ja) 炎症性疾患の予防又は治療剤
AU2018212403A1 (en) TGF-ß decoy receptor
US20260116986A1 (en) Epo receptor agonists and antagonists
US20230086099A1 (en) Combination therapy for treatment of cancer and cancer metastasis
KR20240040068A (ko) 메조텔린을 특이적으로 표적화하는 조작된 면역 세포 및 이의 용도
JP2024531366A (ja) 過体重及び肥満の個体におけるがんの治療のためのｇｐｒ６５標的化
US20190263906A1 (en) Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases
TW201922280A (zh) 用於異位性皮膚炎之抗-il-33 療法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination